Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer
In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office
Cancer society, In Major Restructure, Forms New Executive Committee, Bylaws
Mass. Passes Tobacco Tax, ACS Lauds Victory Over Cigarette Industry
DCE To Provide $3.4 Mil. For Follow-Up Of DES Daughters; Board k’s Tw RFAs, Contracts
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”









